KD PHARMA UK LIMITED
Company number 07614003 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Credit Assessment: KD PHARMA UK LIMITED
1. Credit Opinion: CONDITIONAL
Reasoning: While the company demonstrates positive operational indicators—active status, 13+ year trading history, compliant filings, and operation in a specialized regulated industry—critical financial data necessary for a full credit decision is not available for review. The nominal £1 share capital and ownership by an unlimited entity (which has no statutory filing requirements) present transparency concerns. Credit approval would require production of full financial statements, group structure clarity, and parent company guarantees.
2. Financial Strength
Limited Assessment Available
| Indicator | Observation | Concern Level |
|---|---|---|
| Share Capital | £1.00 nominal | 🔴 High |
| Accounts Filing | Full accounts (not abbreviated) | 🟢 Positive |
| Filing Compliance | Current, not overdue | 🟢 Positive |
| Group Structure | Owned by unlimited company | 🟡 Medium |
| Trading Longevity | 13+ years | 🟢 Positive |
Key Concerns: - Nominal Capital Base: £1 share capital provides virtually no cushion for creditors. This is common in group structures but offers no standalone balance sheet protection. - Unlimited Parent Entity: "Epax Pharma Uk Holdings Unlimited" has no statutory obligation to file accounts at Companies House, creating significant opacity around group financial health and inter-company obligations. - Duplicate PSC Entry: The parent appears listed twice with identical details—likely an administrative error, but warrants clarification. - No Financial Figures: Without balance sheet, P&L, or cash flow data, leverage ratios, net asset positions, and profitability cannot be assessed.
3. Cash Flow Assessment
Unable to Determine — No financial data available for liquidity analysis.
Structural Observations: - Pharmaceutical manufacturing is typically working capital intensive (raw materials, regulatory compliance costs, extended payment terms) - As a subsidiary, cash flow may be significantly influenced by inter-company transactions and group treasury arrangements - The Seal Sands location (industrial chemical/pharmaceutical manufacturing area) suggests physical production operations, implying fixed cost obligations
Critical Data Gaps: - Current ratio / quick ratio - Working capital position - Debtor days and creditor days - Inter-company balances and terms - Parent funding arrangements
4. Monitoring Points
If credit is extended subject to conditions, the following require ongoing monitoring:
| Priority | Metric | Rationale |
|---|---|---|
| 🔴 Critical | Audited financial statements | Must obtain and review full accounts annually |
| 🔴 Critical | Parent company guarantee | Unlimited parent should provide guarantee for material facilities |
| 🔴 Critical | Group structure mapping | Clarify relationship between KD Pharma UK, Epax Pharma UK Holdings Unlimited, and ultimate parent |
| 🟡 High | Inter-company balances | Assess net debtor/creditor position with group entities |
| 🟡 High | Filing timeliness | Early warning indicator if accounts become overdue |
| 🟡 High | Name/ownership changes | Two previous name changes warrant understanding of restructuring rationale |
| 🟢 Medium | Industry regulatory standing | Pharmaceutical manufacturing requires MHRA compliance—verify ongoing status |
| 🟢 Medium | Director changes | Monitor for changes in directorship, particularly given international directors |
Recommended Conditions for Approval: 1. Production of last 3 years' audited financial statements 2. Parent company guarantee from ultimate holding entity 3. Clear group structure chart with financials 4. Quarterly management accounts for facilities >£250k 5. Negative pledge on asset disposals without bank consent